Analyst picks & changes

Biogen Inc.

(BGEN)

David Crossen of UBS Securities initiated coverage with a "buy" and a 12-18 month price target of $60. He anticipates earnings of 31 cents this year and a loss of $1 in

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE